Primary WWOX phosphorylation and JNK activation during etoposide induces cytotoxicity in HEK293 cells

M Jamshidiha1, P Habibollahi, S N Ostad

  • 1Department of Pharmacology-Toxicology, Faculty of Pharmacy.

Abstract

Insights

Etoposide triggers cancer cell death by activating WWOX and JNK pathways. Blocking JNK enhances etoposide

Area of Science:

  • Cancer Biology
  • Molecular Oncology
  • Cellular Stress Response

Background:

  • Etoposide is an antineoplastic drug targeting topoisomerase II.
  • Cellular response to etoposide-induced DNA damage involves stress pathways like JNK.
  • WWOX, a tumor suppressor, is activated by DNA damage.

Purpose of the Study:

  • To investigate the activation patterns of WWOX and JNK upon etoposide treatment.
  • To explore the interaction between WWOX and JNK in response to etoposide.
  • To determine the effect of JNK inhibition on etoposide-induced cytotoxicity.

Main Methods:

  • HEK293 cells were treated with etoposide in a time-course experiment.
  • Western blotting with phospho-specific antibodies assessed WWOX and JNK activation.
  • MTT assay evaluated cell viability under etoposide and JNK inhibitor treatment.

Main Results:

  • WWOX and JNK activation occurred simultaneously following DNA damage.
  • Inhibition of JNK signaling potentiated etoposide-induced cytotoxicity in HEK293 cells.

Conclusions:

  • Etoposide induces cytotoxicity and WWOX phosphorylation.
  • Blocking the JNK pathway enhances etoposide's cytotoxic effects.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...